PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC
Author: sHq_LoGiNz
OAKLAND, Calif.–(BUSINESS WIRE)–Planted has raised $31.8 million to scale autonomous power deployment, with Piva Capital and RA Capital Management Planetary Health co-leading the round and participation from Breakthrough Energy Ventures, Gigascale Capital, Google, and Khosla Ventures. Power demand is rising faster than new capacity can be built. Solar PV remains the largest contributor to new global electricity supply, hitting a record 664 gigawatts in 2025. Still, the world needs terawatts o
BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults. Approved by the U.S. Food and Drug Administration (FDA) in January 2025, JOURNAVX marked the first new class of pain medicine in over 20 years — since then JOURNAVX has been prescribed to over
WASHINGTON–(BUSINESS WIRE)–Deep Fission, Inc. (Nasdaq: FISN) (“Deep Fission” or the “Company”), an advanced nuclear energy company developing small modular pressurized water reactors installed one mile underground, today announced the public release of its Nuclear Safety Design Agreement (NSDA) for the Gravity™ Nuclear Reactor. The U.S. Department of Energy (DOE) approved the NSDA as part of the Company’s Reactor Pilot Program taking place in Parsons, Kansas. The NSDA establishes the safety f
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF – July 14.09.2026 FJUL.LN IE000YJBT6I5 100,002.00 USD 2,920,194.24 29.201
LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari
LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF – October 14.09.2026 FOCT.LN IE0004X8KUG5 100,002.00 USD 2,989,103.16 29.890
LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Emerging Markets AlphaDEX UCITS ETF 14.09.2026 FEM IE00B8X9NX34 300,002.00 USD 15,419,073.50 51.397
